Furie, Richard
Petri, Michelle A
Strand, Vibeke
Gladman, Dafna D
Zhong, Z John
Freimuth, William W
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
FRI0205 ANTIMALARIAL AGENTS IMPROVE PHYSICAL FUNCTIONING IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2019-eular.6430
Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme
https://doi.org/10.1136/lupus-2020-000459
POS0185 BELIMUMAB DISRUPTS MEMORY B-CELL TRAFFICKING IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2022-eular.1820
Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies
https://doi.org/10.1080/14712598.2019.1561856
P128 Efficacy of intravenous belimumab in children with systemic lupus erythematosus with markers of high disease activity: across-trial comparison with adult belimumab studies
https://doi.org/10.1136/lupus-2020-eurolupus.172
LSO-028 Predictors of de novo renal flares in systemic lupus erythematosus – time to revisit belimumab dose for extra-renal disease? Results from five phase III clinical trials of belimumab
https://doi.org/10.1136/lupus-2023-kcr.69
POS0762 CAN THE SLE-DAS SUBSTITUTE BILAG TO MEASURE LUPUS DISEASE ACTIVITY IN CLINICAL TRIALS? POST-HOC ANALYSIS OF THE BLISS-76 TRIAL
https://doi.org/10.1136/annrheumdis-2021-eular.3162
Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy: a post hoc longitudinal study
https://doi.org/10.1136/lupus-2020-000412
PO.5.104 Evaluation of traditional laboratory markers as predictors of renal flares: a post-hoc analysis of four phase iii clinical trials of SLE
https://doi.org/10.1136/lupus-2022-elm2022.128
A Retrospective Administrative Claims Database Evaluation of the Utilization of Belimumab in US Managed Care Settings
https://doi.org/10.1016/j.clinthera.2015.10.008
Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE
https://doi.org/10.1136/lupus-2021-000499
AB1079 BELIMUMAB VERSUS PLACEBO IMPROVES DISEASE ACTIVITY AND REDUCES CUMULATIVE GLUCOCORTICOID DOSE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS WHO WERE TREATMENT RESPONDERS: RESULTS OF A LARGE INTEGRATED ANALYSIS
https://doi.org/10.1136/annrheumdis-2024-eular.1843
OP0297 THE SLE-DAS ENABLES ACCURATE AND USER-FRIENDLY DEFINITIONS OF REMISSION AND CATEGORIES OF LUPUS DISEASE ACTIVITY: DERIVATION AND VALIDATION STUDY IN 1190 SLE PATIENTS
https://doi.org/10.1136/annrheumdis-2021-eular.1677
POS0101 ADVERSE HEALTH-RELATED QUALITY OF LIFE OUTCOME DESPITE ADEQUATE CLINICAL RESPONSE TO TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2021-eular.1472
POS0119 SLE-DAS REMISSION AND LOW DISEASE ACTIVITY STATES ARE ASSOCIATED WITH IMPROVED HEALTH-RELATED QUALITY OF LIFE AND FATIGUE: POST-HOC ANALYSIS OF THE BLISS-52 AND BLISS-76 PHASE III TRIALS.
https://doi.org/10.1136/annrheumdis-2022-eular.3634
FRI0168 ASSOCIATION OF OVERWEIGHT/OBESITY WITH IMPAIRED HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2020-eular.4016
FRI0175 PREDICTORS OF LOW DISEASE ACTIVITY AND CLINICAL REMISSION FOLLOWING BELIMUMAB TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2019-eular.6376
Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis
https://doi.org/10.1136/annrheumdis-2018-214043
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks
https://doi.org/10.1136/lupus-2023-000907
Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity
https://doi.org/10.1136/annrheumdis-2021-220363
PO.7.146 Sensitivity analysis of EQ-5D-3L index scores in relation to discriminative and known-groups validity in systemic lupus erythematosus
https://doi.org/10.1136/lupus-2022-elm2022.166
POS0547 BELIMUMAB EFFICACY IN MUCOCUTANEOUS SYSTEMIC LUPUS ERYTHEMATOSUS: A LARGE POST-HOC ANALYSIS INTEGRATING DATA FROM FIVE PHASE III RANDOMISED CONTROLLED TRIALS
https://doi.org/10.1136/annrheumdis-2024-eular.4849
FRI0198 ANTIMALARIAL AGENTS DIMINISH WHILE METHOTREXATE, AZATHIOPRINE AND MYCOPHENOLIC ACID INCREASE BAFF LEVELS IN SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2019-eular.6414
Belimumab in systemic lupus erythematosus
https://doi.org/10.1136/rmdopen-2014-000011
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison
https://doi.org/10.1136/rmdopen-2021-001747
PO.7.149 Associations between abnormal bmi and patient-reported health-related quality of life before and after therapeutic intervention in patients with systemic lupus erythematosus
https://doi.org/10.1136/lupus-2022-elm2022.169
Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data
https://doi.org/10.1136/lupus-2022-000830
Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus
https://doi.org/10.1136/annrheumdis-2018-214427
Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection
https://doi.org/10.1007/s40268-021-00369-w
Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus
https://doi.org/10.1007/s40268-021-00363-2
Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus
https://doi.org/10.1136/annrheumdis-2019-216367
Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials
https://doi.org/10.1136/lupus-2014-000031
POS1467 PREDICTORS OF NEUROPSYCHIATRIC FLARES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM FIVE PHASE III CLINICAL TRIALS OF BELIMUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.5428
How to use the Lupus Low Disease Activity State (LLDAS) in clinical trials
https://doi.org/10.1136/annrheumdis-2019-215650
Clinical trial data sharing: here’s the challenge
https://doi.org/10.1136/bmjopen-2019-032334
OP0052 PREDICTORS OF RENAL FLARES IN SYSTEMIC LUPUS ERYTHEMATOSUS: A POST-HOC ANALYSIS OF FOUR PHASE III CLINICAL TRIALS OF BELIMUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.6142
POS1156 PREDICTORS OF DE NOVO RENAL FLARES IN SYSTEMIC LUPUS ERYTHEMATOSUS – TIME TO REVISIT BELIMUMAB DOSE FOR EXTRA-RENAL DISEASE? RESULTS FROM FIVE PHASE III CLINICAL TRIALS OF BELIMUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.6006
OP0147 THE SLE-DAS REMISSION AND LOW DISEASE ACTIVITY STATES DISCRIMINATE DRUG FROM PLACEBO AND BETTER HEALTH-RELATED QUALITY OF LIFE: POST-HOC ANALYSIS OF THE BLISS-52 AND BLISS-76 PHASE III TRIALS.
https://doi.org/10.1136/annrheumdis-2022-eular.2769
Established organ damage reduces belimumab efficacy in systemic lupus erythematosus
https://doi.org/10.1136/annrheumdis-2018-214880
LSO-030 Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab
https://doi.org/10.1136/lupus-2023-kcr.71
LSO-068 Association between organ-specific safety of estrogens in lupus erythematosus national assessment-systemic lupus erythematosus (SLE) disease activity index (SELENA-SLEDAI) response to belimumab and SF-36v2 and FACIT-fatigue scores in patients with SLE
https://doi.org/10.1136/lupus-2023-kcr.109
148 Antimalarial agents and other immunosuppressants influence BAFF levels in opposite directions in patients with systemic lupus erythematosus
https://doi.org/10.1136/lupus-2019-lsm.148
SF-36v2 and FACIT-Fatigue quality of life improvements with organ-specific SELENA-SLEDAI response and belimumab treatment in patients with systemic lupus erythematosus
https://doi.org/10.1136/lupus-2023-001118
Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports
https://doi.org/10.1136/ard-2022-222505
Documents that mention this clinical trial
FRI0205 ANTIMALARIAL AGENTS IMPROVE PHYSICAL FUNCTIONING IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2019-eular.6430
Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme
https://doi.org/10.1136/lupus-2020-000459
Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies
https://doi.org/10.1080/14712598.2019.1561856
P128 Efficacy of intravenous belimumab in children with systemic lupus erythematosus with markers of high disease activity: across-trial comparison with adult belimumab studies
https://doi.org/10.1136/lupus-2020-eurolupus.172
LSO-028 Predictors of de novo renal flares in systemic lupus erythematosus – time to revisit belimumab dose for extra-renal disease? Results from five phase III clinical trials of belimumab
https://doi.org/10.1136/lupus-2023-kcr.69
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
https://doi.org/10.1016/s0140-6736(10)61354-2
A Retrospective Administrative Claims Database Evaluation of the Utilization of Belimumab in US Managed Care Settings
https://doi.org/10.1016/j.clinthera.2015.10.008
MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lupus NatIonwide reGistry (LUNA) coHorT
https://doi.org/10.1136/lupus-2022-000746
AB1079 BELIMUMAB VERSUS PLACEBO IMPROVES DISEASE ACTIVITY AND REDUCES CUMULATIVE GLUCOCORTICOID DOSE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS WHO WERE TREATMENT RESPONDERS: RESULTS OF A LARGE INTEGRATED ANALYSIS
https://doi.org/10.1136/annrheumdis-2024-eular.1843
Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy: a post hoc longitudinal study
https://doi.org/10.1136/lupus-2020-000412
POS0101 ADVERSE HEALTH-RELATED QUALITY OF LIFE OUTCOME DESPITE ADEQUATE CLINICAL RESPONSE TO TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2021-eular.1472
FRI0168 ASSOCIATION OF OVERWEIGHT/OBESITY WITH IMPAIRED HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2020-eular.4016
POS0119 SLE-DAS REMISSION AND LOW DISEASE ACTIVITY STATES ARE ASSOCIATED WITH IMPROVED HEALTH-RELATED QUALITY OF LIFE AND FATIGUE: POST-HOC ANALYSIS OF THE BLISS-52 AND BLISS-76 PHASE III TRIALS.
https://doi.org/10.1136/annrheumdis-2022-eular.3634
FRI0175 PREDICTORS OF LOW DISEASE ACTIVITY AND CLINICAL REMISSION FOLLOWING BELIMUMAB TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2019-eular.6376
PO.7.146 Sensitivity analysis of EQ-5D-3L index scores in relation to discriminative and known-groups validity in systemic lupus erythematosus
https://doi.org/10.1136/lupus-2022-elm2022.166
POS0547 BELIMUMAB EFFICACY IN MUCOCUTANEOUS SYSTEMIC LUPUS ERYTHEMATOSUS: A LARGE POST-HOC ANALYSIS INTEGRATING DATA FROM FIVE PHASE III RANDOMISED CONTROLLED TRIALS
https://doi.org/10.1136/annrheumdis-2024-eular.4849
Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis
https://doi.org/10.1136/annrheumdis-2018-214043
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks
https://doi.org/10.1136/lupus-2023-000907
FRI0198 ANTIMALARIAL AGENTS DIMINISH WHILE METHOTREXATE, AZATHIOPRINE AND MYCOPHENOLIC ACID INCREASE BAFF LEVELS IN SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2019-eular.6414
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison
https://doi.org/10.1136/rmdopen-2021-001747
Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus
https://doi.org/10.1136/annrheumdis-2018-214427
PO.7.149 Associations between abnormal bmi and patient-reported health-related quality of life before and after therapeutic intervention in patients with systemic lupus erythematosus
https://doi.org/10.1136/lupus-2022-elm2022.169
Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data
https://doi.org/10.1136/lupus-2022-000830
Belimumab in systemic lupus erythematosus
https://doi.org/10.1136/rmdopen-2014-000011
Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus
https://doi.org/10.1007/s40268-021-00363-2
How to use the Lupus Low Disease Activity State (LLDAS) in clinical trials
https://doi.org/10.1136/annrheumdis-2019-215650
Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials
https://doi.org/10.1136/lupus-2014-000031
POS1467 PREDICTORS OF NEUROPSYCHIATRIC FLARES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM FIVE PHASE III CLINICAL TRIALS OF BELIMUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.5428
Clinical trial data sharing: here’s the challenge
https://doi.org/10.1136/bmjopen-2019-032334
Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus
https://doi.org/10.1136/annrheumdis-2019-216367
Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection
https://doi.org/10.1007/s40268-021-00369-w
OP0147 THE SLE-DAS REMISSION AND LOW DISEASE ACTIVITY STATES DISCRIMINATE DRUG FROM PLACEBO AND BETTER HEALTH-RELATED QUALITY OF LIFE: POST-HOC ANALYSIS OF THE BLISS-52 AND BLISS-76 PHASE III TRIALS.
https://doi.org/10.1136/annrheumdis-2022-eular.2769
Established organ damage reduces belimumab efficacy in systemic lupus erythematosus
https://doi.org/10.1136/annrheumdis-2018-214880
OP0052 PREDICTORS OF RENAL FLARES IN SYSTEMIC LUPUS ERYTHEMATOSUS: A POST-HOC ANALYSIS OF FOUR PHASE III CLINICAL TRIALS OF BELIMUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.6142
POS1156 PREDICTORS OF DE NOVO RENAL FLARES IN SYSTEMIC LUPUS ERYTHEMATOSUS – TIME TO REVISIT BELIMUMAB DOSE FOR EXTRA-RENAL DISEASE? RESULTS FROM FIVE PHASE III CLINICAL TRIALS OF BELIMUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.6006
LSO-030 Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab
https://doi.org/10.1136/lupus-2023-kcr.71
LSO-068 Association between organ-specific safety of estrogens in lupus erythematosus national assessment-systemic lupus erythematosus (SLE) disease activity index (SELENA-SLEDAI) response to belimumab and SF-36v2 and FACIT-fatigue scores in patients with SLE
https://doi.org/10.1136/lupus-2023-kcr.109
SF-36v2 and FACIT-Fatigue quality of life improvements with organ-specific SELENA-SLEDAI response and belimumab treatment in patients with systemic lupus erythematosus
https://doi.org/10.1136/lupus-2023-001118
148 Antimalarial agents and other immunosuppressants influence BAFF levels in opposite directions in patients with systemic lupus erythematosus
https://doi.org/10.1136/lupus-2019-lsm.148
Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports
https://doi.org/10.1136/ard-2022-222505
Documents that mention this clinical trial
POS0185 BELIMUMAB DISRUPTS MEMORY B-CELL TRAFFICKING IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2022-eular.1820
FRI0205 ANTIMALARIAL AGENTS IMPROVE PHYSICAL FUNCTIONING IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2019-eular.6430
P128 Efficacy of intravenous belimumab in children with systemic lupus erythematosus with markers of high disease activity: across-trial comparison with adult belimumab studies
https://doi.org/10.1136/lupus-2020-eurolupus.172
Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies
https://doi.org/10.1080/14712598.2019.1561856
LSO-028 Predictors of de novo renal flares in systemic lupus erythematosus – time to revisit belimumab dose for extra-renal disease? Results from five phase III clinical trials of belimumab
https://doi.org/10.1136/lupus-2023-kcr.69
Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme
https://doi.org/10.1136/lupus-2020-000459
POS0762 CAN THE SLE-DAS SUBSTITUTE BILAG TO MEASURE LUPUS DISEASE ACTIVITY IN CLINICAL TRIALS? POST-HOC ANALYSIS OF THE BLISS-76 TRIAL
https://doi.org/10.1136/annrheumdis-2021-eular.3162
Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy: a post hoc longitudinal study
https://doi.org/10.1136/lupus-2020-000412
PO.5.104 Evaluation of traditional laboratory markers as predictors of renal flares: a post-hoc analysis of four phase iii clinical trials of SLE
https://doi.org/10.1136/lupus-2022-elm2022.128
A Retrospective Administrative Claims Database Evaluation of the Utilization of Belimumab in US Managed Care Settings
https://doi.org/10.1016/j.clinthera.2015.10.008
Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE
https://doi.org/10.1136/lupus-2021-000499
AB1079 BELIMUMAB VERSUS PLACEBO IMPROVES DISEASE ACTIVITY AND REDUCES CUMULATIVE GLUCOCORTICOID DOSE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS WHO WERE TREATMENT RESPONDERS: RESULTS OF A LARGE INTEGRATED ANALYSIS
https://doi.org/10.1136/annrheumdis-2024-eular.1843
OP0297 THE SLE-DAS ENABLES ACCURATE AND USER-FRIENDLY DEFINITIONS OF REMISSION AND CATEGORIES OF LUPUS DISEASE ACTIVITY: DERIVATION AND VALIDATION STUDY IN 1190 SLE PATIENTS
https://doi.org/10.1136/annrheumdis-2021-eular.1677
POS0101 ADVERSE HEALTH-RELATED QUALITY OF LIFE OUTCOME DESPITE ADEQUATE CLINICAL RESPONSE TO TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2021-eular.1472
FRI0168 ASSOCIATION OF OVERWEIGHT/OBESITY WITH IMPAIRED HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2020-eular.4016
POS0119 SLE-DAS REMISSION AND LOW DISEASE ACTIVITY STATES ARE ASSOCIATED WITH IMPROVED HEALTH-RELATED QUALITY OF LIFE AND FATIGUE: POST-HOC ANALYSIS OF THE BLISS-52 AND BLISS-76 PHASE III TRIALS.
https://doi.org/10.1136/annrheumdis-2022-eular.3634
FRI0175 PREDICTORS OF LOW DISEASE ACTIVITY AND CLINICAL REMISSION FOLLOWING BELIMUMAB TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2019-eular.6376
PO.7.146 Sensitivity analysis of EQ-5D-3L index scores in relation to discriminative and known-groups validity in systemic lupus erythematosus
https://doi.org/10.1136/lupus-2022-elm2022.166
POS0547 BELIMUMAB EFFICACY IN MUCOCUTANEOUS SYSTEMIC LUPUS ERYTHEMATOSUS: A LARGE POST-HOC ANALYSIS INTEGRATING DATA FROM FIVE PHASE III RANDOMISED CONTROLLED TRIALS
https://doi.org/10.1136/annrheumdis-2024-eular.4849
Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis
https://doi.org/10.1136/annrheumdis-2018-214043
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks
https://doi.org/10.1136/lupus-2023-000907
Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity
https://doi.org/10.1136/annrheumdis-2021-220363
FRI0198 ANTIMALARIAL AGENTS DIMINISH WHILE METHOTREXATE, AZATHIOPRINE AND MYCOPHENOLIC ACID INCREASE BAFF LEVELS IN SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2019-eular.6414
Belimumab in systemic lupus erythematosus
https://doi.org/10.1136/rmdopen-2014-000011
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison
https://doi.org/10.1136/rmdopen-2021-001747
PO.7.149 Associations between abnormal bmi and patient-reported health-related quality of life before and after therapeutic intervention in patients with systemic lupus erythematosus
https://doi.org/10.1136/lupus-2022-elm2022.169
Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data
https://doi.org/10.1136/lupus-2022-000830
Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus
https://doi.org/10.1136/annrheumdis-2018-214427
Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection
https://doi.org/10.1007/s40268-021-00369-w
Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus
https://doi.org/10.1007/s40268-021-00363-2
Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus
https://doi.org/10.1136/annrheumdis-2019-216367
Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials
https://doi.org/10.1136/lupus-2014-000031
POS1467 PREDICTORS OF NEUROPSYCHIATRIC FLARES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM FIVE PHASE III CLINICAL TRIALS OF BELIMUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.5428
How to use the Lupus Low Disease Activity State (LLDAS) in clinical trials
https://doi.org/10.1136/annrheumdis-2019-215650
Clinical trial data sharing: here’s the challenge
https://doi.org/10.1136/bmjopen-2019-032334
OP0052 PREDICTORS OF RENAL FLARES IN SYSTEMIC LUPUS ERYTHEMATOSUS: A POST-HOC ANALYSIS OF FOUR PHASE III CLINICAL TRIALS OF BELIMUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.6142
POS1156 PREDICTORS OF DE NOVO RENAL FLARES IN SYSTEMIC LUPUS ERYTHEMATOSUS – TIME TO REVISIT BELIMUMAB DOSE FOR EXTRA-RENAL DISEASE? RESULTS FROM FIVE PHASE III CLINICAL TRIALS OF BELIMUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.6006
OP0147 THE SLE-DAS REMISSION AND LOW DISEASE ACTIVITY STATES DISCRIMINATE DRUG FROM PLACEBO AND BETTER HEALTH-RELATED QUALITY OF LIFE: POST-HOC ANALYSIS OF THE BLISS-52 AND BLISS-76 PHASE III TRIALS.
https://doi.org/10.1136/annrheumdis-2022-eular.2769
Established organ damage reduces belimumab efficacy in systemic lupus erythematosus
https://doi.org/10.1136/annrheumdis-2018-214880
LSO-030 Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab
https://doi.org/10.1136/lupus-2023-kcr.71
LSO-068 Association between organ-specific safety of estrogens in lupus erythematosus national assessment-systemic lupus erythematosus (SLE) disease activity index (SELENA-SLEDAI) response to belimumab and SF-36v2 and FACIT-fatigue scores in patients with SLE
https://doi.org/10.1136/lupus-2023-kcr.109
148 Antimalarial agents and other immunosuppressants influence BAFF levels in opposite directions in patients with systemic lupus erythematosus
https://doi.org/10.1136/lupus-2019-lsm.148
SF-36v2 and FACIT-Fatigue quality of life improvements with organ-specific SELENA-SLEDAI response and belimumab treatment in patients with systemic lupus erythematosus
https://doi.org/10.1136/lupus-2023-001118
Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports
https://doi.org/10.1136/ard-2022-222505